MX2018005689A - Administracion intratecal de secuencias de acido nucleico que codifican abcd1 para el tratamiento de la adrenomieloneuropatia. - Google Patents
Administracion intratecal de secuencias de acido nucleico que codifican abcd1 para el tratamiento de la adrenomieloneuropatia.Info
- Publication number
- MX2018005689A MX2018005689A MX2018005689A MX2018005689A MX2018005689A MX 2018005689 A MX2018005689 A MX 2018005689A MX 2018005689 A MX2018005689 A MX 2018005689A MX 2018005689 A MX2018005689 A MX 2018005689A MX 2018005689 A MX2018005689 A MX 2018005689A
- Authority
- MX
- Mexico
- Prior art keywords
- adrenomyeloneuropathy
- treatment
- nucleic acid
- acid sequences
- sequences encoding
- Prior art date
Links
- 201000011452 Adrenoleukodystrophy Diseases 0.000 title abstract 5
- 208000018126 Adrenomyeloneuropathy Diseases 0.000 title abstract 3
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 238000007913 intrathecal administration Methods 0.000 title 1
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 abstract 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 abstract 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
Abstract
Métodos de la invención abarcan la administración de secuencias de ácido nucleico que codifican ABCD1 para el tratamiento de la adrenoleucodistrofia ligada al cromosoma X (X-ALD), por ejemplo, para la adrenomieloneuropatía (AMN).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562251208P | 2015-11-05 | 2015-11-05 | |
US201662300691P | 2016-02-26 | 2016-02-26 | |
PCT/US2016/060375 WO2017079467A1 (en) | 2015-11-05 | 2016-11-03 | Intrathecal delivery of nucleic acid sequences encoding abcd1 for treatment of adrenomyeloneuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005689A true MX2018005689A (es) | 2018-08-01 |
Family
ID=58662371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005689A MX2018005689A (es) | 2015-11-05 | 2016-11-03 | Administracion intratecal de secuencias de acido nucleico que codifican abcd1 para el tratamiento de la adrenomieloneuropatia. |
Country Status (15)
Country | Link |
---|---|
US (3) | US20180320176A1 (es) |
EP (2) | EP4066862A1 (es) |
JP (2) | JP7037490B2 (es) |
KR (1) | KR20180066252A (es) |
CN (2) | CN118267490A (es) |
AU (1) | AU2016349381B2 (es) |
BR (1) | BR112018008993A2 (es) |
CA (1) | CA3003747A1 (es) |
ES (1) | ES2916325T3 (es) |
IL (1) | IL258904B (es) |
MX (1) | MX2018005689A (es) |
PL (1) | PL3370705T3 (es) |
RU (2) | RU2739384C2 (es) |
SG (1) | SG11201803353PA (es) |
WO (1) | WO2017079467A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022008201A (es) * | 2019-12-31 | 2022-10-18 | Swanbio Therapeutics Ltd | Construcciones mejoradas de aav-abcd1 y su uso para su tratamiento o prevención de adrenoleucodistrofia (ald) y/o adrenomieloneuropatía (amn). |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
US5869039A (en) * | 1993-10-15 | 1999-02-09 | Institut National De La Sante Et De La Recherche Medicale | X-linked adrenoleukodystrophy gene and corresponding protein |
US6132420A (en) | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6156331A (en) | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
DE69720190T2 (de) | 1996-02-02 | 2003-12-11 | Alza Corp | Implantierbares system mit verzögerter freisetzung von leuprolid |
US6261584B1 (en) | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6713300B1 (en) * | 1997-02-27 | 2004-03-30 | University Of Utah Research Foundation | Nucleic acid and amino acid sequences for ATP-binding cassette transporter and methods of screening for agents that modify ATP-binding cassette transporter |
ZA981610B (en) | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
MY125849A (en) | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
AU1623099A (en) | 1997-12-22 | 1999-07-12 | Alza Corporation | Rate controlling membranes for controlled drug delivery devices |
DE69822208T2 (de) | 1997-12-29 | 2005-04-28 | Alza Corp., Mountain View | Osmotisches verabreichungssystem mit stöpselrückhaltemechanismus |
AU8493998A (en) | 1997-12-30 | 1999-07-19 | Alza Corporation | Beneficial agent delivery system with membrane plug |
WO2000040218A2 (en) | 1998-12-31 | 2000-07-13 | Alza Corporation | Osmotic delivery system having space efficient piston |
US6225525B1 (en) * | 1999-10-13 | 2001-05-01 | Ortho-Mcneil Pharmaceutical, Inc. | ATP-binding cassette transporter (ABC1) modified transgenic mice |
ATE306908T1 (de) | 1999-12-21 | 2005-11-15 | Alza Corp | Ventil für osmotische vorrichtungen |
US7163688B2 (en) | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
WO2003004660A1 (en) * | 2001-07-03 | 2003-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods of administering vectors to synaptically connected neurons |
AU2003256308B2 (en) | 2002-06-26 | 2008-07-03 | Intarcia Therapeutics, Inc. | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
US7014636B2 (en) | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
AU2004227985B2 (en) | 2003-03-31 | 2009-04-02 | Intarcia Therapeutics, Inc. | Osmotic pump with means for dissipating internal pressure |
US20050175701A1 (en) | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
WO2011106376A2 (en) * | 2010-02-23 | 2011-09-01 | The General Hospital Corporation | Use of microvesicles in the treatment of medical conditions |
WO2012170911A2 (en) * | 2011-06-10 | 2012-12-13 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
US8999380B2 (en) * | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9827295B2 (en) * | 2013-05-15 | 2017-11-28 | Regents Of The University Of Minnesota | Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase |
GB201401707D0 (en) * | 2014-01-31 | 2014-03-19 | Sec Dep For Health The | Adeno-associated viral vectors |
-
2016
- 2016-11-03 JP JP2018543041A patent/JP7037490B2/ja active Active
- 2016-11-03 US US15/773,337 patent/US20180320176A1/en not_active Abandoned
- 2016-11-03 RU RU2018120484A patent/RU2739384C2/ru active
- 2016-11-03 CA CA3003747A patent/CA3003747A1/en active Pending
- 2016-11-03 PL PL16862990.5T patent/PL3370705T3/pl unknown
- 2016-11-03 EP EP22159649.7A patent/EP4066862A1/en not_active Withdrawn
- 2016-11-03 BR BR112018008993A patent/BR112018008993A2/pt active Search and Examination
- 2016-11-03 ES ES16862990T patent/ES2916325T3/es active Active
- 2016-11-03 CN CN202410225929.8A patent/CN118267490A/zh active Pending
- 2016-11-03 MX MX2018005689A patent/MX2018005689A/es unknown
- 2016-11-03 CN CN201680077741.7A patent/CN108472264A/zh active Pending
- 2016-11-03 WO PCT/US2016/060375 patent/WO2017079467A1/en active Application Filing
- 2016-11-03 EP EP16862990.5A patent/EP3370705B1/en active Active
- 2016-11-03 IL IL258904A patent/IL258904B/en unknown
- 2016-11-03 KR KR1020187015254A patent/KR20180066252A/ko not_active Application Discontinuation
- 2016-11-03 RU RU2020141860A patent/RU2020141860A/ru unknown
- 2016-11-03 SG SG11201803353PA patent/SG11201803353PA/en unknown
- 2016-11-03 AU AU2016349381A patent/AU2016349381B2/en active Active
-
2019
- 2019-04-02 US US16/373,081 patent/US10519445B2/en active Active
-
2022
- 2022-01-17 JP JP2022005016A patent/JP2022064910A/ja active Pending
-
2023
- 2023-04-04 US US18/295,566 patent/US20230365967A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11201803353PA (en) | 2018-05-30 |
EP3370705A4 (en) | 2019-05-15 |
US20230365967A1 (en) | 2023-11-16 |
EP4066862A1 (en) | 2022-10-05 |
WO2017079467A1 (en) | 2017-05-11 |
RU2020141860A (ru) | 2021-04-01 |
RU2018120484A (ru) | 2019-12-05 |
AU2016349381B2 (en) | 2023-02-23 |
RU2018120484A3 (es) | 2020-03-11 |
US20190225967A1 (en) | 2019-07-25 |
CN118267490A (zh) | 2024-07-02 |
ES2916325T3 (es) | 2022-06-30 |
AU2016349381A1 (en) | 2018-06-21 |
CA3003747A1 (en) | 2017-05-11 |
EP3370705A1 (en) | 2018-09-12 |
EP3370705B1 (en) | 2022-03-09 |
JP2022064910A (ja) | 2022-04-26 |
US20180320176A1 (en) | 2018-11-08 |
CN108472264A (zh) | 2018-08-31 |
PL3370705T3 (pl) | 2022-08-01 |
JP2018537124A (ja) | 2018-12-20 |
IL258904B (en) | 2022-09-01 |
JP7037490B2 (ja) | 2022-03-16 |
KR20180066252A (ko) | 2018-06-18 |
RU2739384C2 (ru) | 2020-12-23 |
US10519445B2 (en) | 2019-12-31 |
IL258904A (en) | 2018-06-28 |
BR112018008993A2 (pt) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201613859A (en) | Analogs of PRIDOPIDINE, their preparation and use | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
MX2016011160A (es) | Tratamiento de afecciones asociadas con la hiperinsulinemia. | |
EP3135668A4 (en) | Novel disubstituted 1, 2, 4-triazine compound | |
MX369501B (es) | Proceso para la preparación de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno. | |
AU2015339087B2 (en) | Trifluoromethyl alcohols as modulators of RORyt | |
PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
MX2016015543A (es) | Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno. | |
EP3125886A4 (en) | Disubstituted triazole analogs | |
NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
EP3148474A4 (en) | DEVICE FOR OBTAINING MOLARDISTALLIZATION | |
NZ732704A (en) | Quinoline carboxamides for use in the treatment of leukemia | |
CL2016001745A1 (es) | Ácido (s)-3'-metil-abscísico y ésteres del mismo | |
EP3193610A4 (en) | Selective nav1.7 inhibitors for the treatment of diabetes | |
UA117524C2 (uk) | Стимулятори рослин, їх застосування та спосіб стимуляції рослин | |
EP3094347A4 (en) | Methods for enhancing the delivery of active agents | |
MX2018012900A (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
MX2018012904A (es) | Uso de beta-agonistas del receptor de la hormona tiroidea. | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
MX2018005689A (es) | Administracion intratecal de secuencias de acido nucleico que codifican abcd1 para el tratamiento de la adrenomieloneuropatia. | |
MX2016015298A (es) | Inhibidores de nampt y metodos. | |
NZ719451A (en) | Glucagon analog for treatment of severe hypoglycemia | |
WO2016040313A3 (en) | Methods of treating cancer comprising administering a ppar-gamma agonist |